BeiGene Ltd (FRA:49BA)
€ 152 5 (3.4%) Market Cap: 15.89 Bil Enterprise Value: 14.28 Bil PE Ratio: 0 PB Ratio: 5.18 GF Score: 69/100

Beigene Ltd at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 05:30PM GMT
Release Date Price: €113
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So great. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures, so you can pick up a copy at the registration desk.

So pleased to have BeiGene with me for our next session, John Oyler, the CEO; and Howard Liang, CFO. John, I don't know, do you want to make any opening comments? Or should we just jump right into it?

John V. Oyler
BeiGene, Ltd. - Co-Founder, Chairman & CEO

It's great to be here.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Okay. Good. So look, I thought we'd start off with just sort of a couple of big picture

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot